Jason Harris

There were nearly identical response rates and toxicity with subcutaneous administration of Rituxan (rituximab) and IV administration of the drug to treat follicular lymphoma in the first-line setting, according to results from the phase 3 SABRINA trial that were published in The Lancet Haematology.

Experts discuss how to have the best chances for a complete response for patients with chronic lymphocytic leukemia (CLL) who developed Hodgkin lymphoma (HL).

Black and Latina women with ovarian cancer were less likely than white women to enroll in hospice care within the last 30 days.

Many survivors of Ewing sarcoma have few complications and long-term side effects later on, according to a recent study.

Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a randomized, double-blind phase 3 study that compared 10 mg/kg Yervoy (ipilimumab) or a lower dose of the anti-CTLA-4 anticlonal antibody.

The USPSTF may be changing its stance on PSA screening for prostate cancer.

The PD-1 inhibitor, Opdivo, may be a promising option for patients with advanced anal cancer, according to a recent study.

Patients with early, HER2-positive breast cancer were found to be more likely to respond to the dual HER2-blockade, according to a recent study.

The BTK inhibitor Imbruvica (ibrutinib) was granted a supplemental new drug application (sNDA) by the Food and Drug Administration for the treatment of patients with chronic graft-versus-host-disease (cGVHD).